Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Sold by XTX Topco Ltd

XTX Topco Ltd trimmed its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) by 20.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,906 shares of the company’s stock after selling 5,244 shares during the quarter. XTX Topco Ltd’s holdings in Cytek Biosciences were worth $136,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Barclays PLC boosted its holdings in Cytek Biosciences by 7.0% in the fourth quarter. Barclays PLC now owns 215,424 shares of the company’s stock valued at $1,397,000 after purchasing an additional 14,065 shares in the last quarter. Sterling Capital Management LLC boosted its holdings in Cytek Biosciences by 799.8% in the fourth quarter. Sterling Capital Management LLC now owns 3,887 shares of the company’s stock valued at $25,000 after purchasing an additional 3,455 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Cytek Biosciences in the fourth quarter valued at approximately $765,000. Renaissance Technologies LLC boosted its holdings in Cytek Biosciences by 118.6% in the fourth quarter. Renaissance Technologies LLC now owns 462,600 shares of the company’s stock valued at $3,002,000 after purchasing an additional 251,000 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in Cytek Biosciences by 3.8% in the fourth quarter. Legal & General Group Plc now owns 313,037 shares of the company’s stock valued at $2,032,000 after purchasing an additional 11,346 shares in the last quarter. 69.46% of the stock is owned by institutional investors and hedge funds.

Cytek Biosciences Stock Performance

NASDAQ CTKB opened at $3.75 on Wednesday. The firm has a market cap of $480.36 million, a PE ratio of -46.87 and a beta of 1.41. Cytek Biosciences, Inc. has a one year low of $3.27 and a one year high of $7.63. The firm’s fifty day moving average is $4.08 and its two-hundred day moving average is $5.34.

Wall Street Analyst Weigh In

CTKB has been the topic of a number of recent research reports. The Goldman Sachs Group set a $5.25 target price on shares of Cytek Biosciences in a report on Sunday, February 2nd. Stephens restated an “overweight” rating and issued a $6.00 price objective on shares of Cytek Biosciences in a research note on Wednesday, March 19th. Finally, Piper Sandler dropped their price objective on shares of Cytek Biosciences from $8.50 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th.

About Cytek Biosciences

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.